Cargando…

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

INTRODUCTION: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved gastrointestinal (GI) tolerability and low (< 1%) treatment discontinuati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wray, Sibyl, Then Bergh, Florian, Wundes, Annette, Arnold, Douglas L., Drulovic, Jelena, Jasinska, Elzbieta, Bowen, James D., Negroski, Donald, Naismith, Robert T., Hunter, Samuel F., Gudesblatt, Mark, Chen, Hailu, Lyons, Jennifer, Shankar, Sai L., Kapadia, Shivani, Mendoza, Jason P., Singer, Barry A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870078/ https://www.ncbi.nlm.nih.gov/pubmed/35211872 http://dx.doi.org/10.1007/s12325-022-02068-7

Ejemplares similares

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Naismith, Robert T, et al.
Publicado: (2019)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
por: Wundes, Annette, et al.
Publicado: (2021)

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews
por: Gudesblatt, Mark, et al.
Publicado: (2022)

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
por: Naismith, Robert T., et al.
Publicado: (2020)

Diroximel fumarate for multiple sclerosis
Publicado: (2022)

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis
por: Kuchimanchi, Mita, et al.
Publicado: (2022)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate
por: Gül, Sedat, et al.
Publicado: (2023)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Lager, Brittney, et al.
Publicado: (2023)

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
por: Palte, Michael J., et al.
Publicado: (2019)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Nieto-Gómez, Pelayo, et al.
Publicado: (2023)

The DRF motif of CXCR6 as chemokine receptor adaptation to adhesion
por: Koenen, Andrea, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Expression Analysis of the TdDRF1 Gene in Field-Grown Durum Wheat under Full and Reduced Irrigation
por: Latini, Arianna, et al.
Publicado: (2022)

Risk Factors for Complications following Volar Locking Plate (VLP) Fixation of Unstable Distal Radius Fracture (DRF)
por: Zhu, Yanbin, et al.
Publicado: (2022)

DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells
por: Satyanarayana, Chitkala, et al.
Publicado: (2004)

Chk1 Inhibition of the Replication Factor Drf1 Guarantees Cell-Cycle Elongation at the Xenopus laevis Mid-blastula Transition
por: Collart, Clara, et al.
Publicado: (2017)

Incidence and risk factors for surgical site infection following volar locking plating (VLP) of unstable distal radius fracture (DRF)
por: Meng, Hongyu, et al.
Publicado: (2022)

Tracheal epithelium cell volume responses to hyperosmolar, isosmolar and hypoosmolar solutions: relation to epithelium-derived relaxing factor (EpDRF) effects
por: Fedan, Jeffrey S., et al.
Publicado: (2013)

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
por: Gold, Ralf, et al.
Publicado: (2021)

17. Ultrasound-guided Supraclavicular Block (USGB) by Surgeon for ORIF of Distal Radius Fractures (DRF): A 6-year Experience with 1830 Consecutive Cases
por: Calva-Cerqueira, Daniel, et al.
Publicado: (2023)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
por: Naismith, Robert T, et al.
Publicado: (2019)

Bis(oxotremorine) fumarate bis(fumaric acid)
por: Naeem, Marilyn, et al.
Publicado: (2022)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
por: Longbrake, Erin E, et al.
Publicado: (2020)

Opipramolium fumarate
por: Siddegowda, M. S., et al.
Publicado: (2011)

Imidazolium fumarate
por: Moreno-Fuquen, Rodolfo, et al.
Publicado: (2009)

Cinnarizinium fumarate
por: Kavitha, C. N., et al.
Publicado: (2012)

Fumarates in dermatology
por: Rajagopalan, Murlidhar
Publicado: (2011)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

Psicología del fumar
por: Stäcker, Karl-Heinz 1931-
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_73h4qbh62uerq15a6aa0fomp6b